iSpecimen Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from iSpecimen Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 3.2 times its market value (net cash). Higher than 98% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 1,800% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 92% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-2.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 58% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 81%
Sales fell 81% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-81% / -61%In 3 years sales changed by -81% while total assets changed by -61%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-74.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 79% of Healthcare companies in United States.
Cash Cushion Ratio
3.2× cashCash, after subtracting all debt, is 3.2 times its market value (net cash).
Higher than 98% of Healthcare companies in United States.
Tangible Assets Ratio
76%Of every $100 the company owns, $76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 56% of Healthcare companies in United States.
Tangible Net Worth Ratio
26%Of every $100 of net worth, $26 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 62% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
iSpecimen Inc. made a loss over the last year. iSpecimen Inc. owes $0.77 for every $1 it owns. iSpecimen Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossiSpecimen Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.19The share price is 1.19 times iSpecimen Inc.'s book value per share, lower than 75% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of iSpecimen Inc.'s shares at today's price (share price × number of shares), smaller than 98% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$2 MWhat iSpecimen Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.69Net worth divided by the number of shares. The share price of $0.82 is 1.2 times this, which is the P/B above.
Return on equity (ROE)
-968.5%iSpecimen Inc. lost 968.5% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
Owes vs Owns
0.77×iSpecimen Inc. owes $0.77 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Dividend yield
NoneiSpecimen Inc. does not currently pay a dividend.
Revenue growth
-79%Revenue fell 79% in the year to Dec 2025, and shrank 43% a year on average over 3 years.
Profit growth
LossiSpecimen Inc. made a loss in each of the last two years.
Profit margin
-543.7%iSpecimen Inc. lost $544 for every $100 of revenue.
Interest cover
Not coverediSpecimen Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashiSpecimen Inc. held $7 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For iSpecimen Inc.: $2 M ÷ $2 M (30 Jun 2026) = 1.2.
What is iSpecimen Inc.'s return on equity?
iSpecimen Inc. lost 968.5% of its shareholders' money over the last year, lower than 97% of Healthcare companies in United States.
How much does iSpecimen Inc. owe compared with what it owns?
iSpecimen Inc. owes $0.77 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Does iSpecimen Inc. pay a dividend?
No. iSpecimen Inc. does not currently pay a dividend.
Is iSpecimen Inc.'s revenue growing?
Revenue fell 79% in the year to Dec 2025, and shrank 43% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.